Novel Therapies for Relapsed or Refractory HER2-Positive Metastatic Breast Cancer

Download All
In this this dynamic program on the optimal treatment of patients with relapsed or refractory HER2-positive advanced breast cancer, renowned breast cancer experts review and discuss key clinical data and patient case studies and look ahead at promising agents that may soon change practice.
Thomas Bachelot, MD, PhD
Adam M. Brufsky, MD, PhD
person default
Cristina Saura, MD, PhD

Downloadable Slidesets

Download this slideset on the new and emerging antibody drug conjugates for HER2-postive MBC.

Adam M. Brufsky, MD, PhD Released: May 29, 2020

Download this slideset on newer TKIs for relapsed or refractory HER2-positive metastatic breast cancer.

person default Cristina Saura, MD, PhD Released: May 29, 2020

Download this slideset covering a novel HER2-targeted antibody and case discussions for managing progressive HER2-positive MBC with new therapies.

Thomas Bachelot, MD, PhD Released: May 29, 2020

Download this short summary slideset of key takeaway points from a live presentation on the novel therapies for relapsed or refractory HER2-postivie metastatic breast cancer.

Thomas Bachelot, MD, PhD Adam M. Brufsky, MD, PhD person default Cristina Saura, MD, PhD Released: May 29, 2020
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Daiichi Sankyo, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue